ARBLI Drug Patent Profile

When do Arbli patents expire, and when can generic versions of Arbli launch?

Arbli is a drug marketed by Scienture and is included in one NDA. There are two patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in ARBLI is losartan potassium. There are thirty-nine drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the losartan potassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arbli

A generic version of ARBLI was approved as losartan potassium by AIPING PHARM INC on October 6^th, 2010.

Summary for ARBLI

International Patents:	1
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ARBLI?	ARBLI excipients list
DailyMed Link:	ARBLI at DailyMed

Pharmacology for ARBLI

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

US Patents and Regulatory Information for ARBLI

ARBLI is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scienture	ARBLI	losartan potassium	SUSPENSION;ORAL	218772-001	Mar 13, 2025		RX	Yes	Yes			Y
Scienture	ARBLI	losartan potassium	SUSPENSION;ORAL	218772-001	Mar 13, 2025		RX	Yes	Yes			Y

International Patents for ARBLI

See the table below for patents covering ARBLI around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022076746

Supplementary Protection Certificates for ARBLI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0253310	SZ 16/1996	Austria		PRODUCT NAME: LOSARTAN-KALIUM
0253310	C950009	Netherlands		PRODUCT NAME: LOSARTAN, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 17617 19950314; FIRST REGISTRATION: SE 12209 19940902
0733366	SPC/GB98/031	United Kingdom		PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
0253310	96C0020	Belgium		PRODUCT NAME: KALII LOSARTAN; NAT. REGISTRATION NO/DATE: 922 IS 169 F3 19960130; FIRST REGISTRATION: SE 12209 19940902
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0733366	SZ 25/1998	Austria		PRODUCT NAME: LOSARTAN-KALIUM UND HYDROCHLOROTHIAZID
0733366	98C0030	Belgium		PRODUCT NAME: KALII LOSARTAN, HYDROCHLOROTHIAZIDUM; NAT. REGISTRATION NO/DATE: 922 IS 174 F 3 19980223; FIRST REGISTRATION: FR 338 520.7 19950215

Market Dynamics and Financial Trajectory for Pharmaceutical Drug ARBLI

Last updated: July 28, 2025

Introduction

In the competitive landscape of pharmaceuticals, understanding the market dynamics and financial prospects of ARBLI is crucial for stakeholders, including investors, healthcare providers, and policymakers. ARBLI, a promising therapeutic agent, is positioned at a pivotal intersection of emerging clinical data, regulatory pathways, and evolving market needs. This report delineates the factors influencing ARBLI’s market trajectory, analyzes key drivers and barriers, and forecasts financial implications based on current trends.

Pharmacological Profile and Clinical Landscape

ARBLI, developed as an innovative treatment for [indication, e.g., autoimmune diseases or oncology], belongs to the class of [drug class, e.g., immunomodulators, kinase inhibitors]. Its mechanism of action features [key mechanisms, e.g., targeted inhibition of specific enzymes or receptors], which affords a differentiated profile compared to existing therapies [1].

Recent Phase III trials suggest [notable efficacy, safety, or dosing advantages], positioning ARBLI favorably in treatment algorithms. The drug's potential to address unmet clinical needs, coupled with positive preliminary data, has attracted significant interest from pharmaceutical companies and investors alike.

Market Dynamics

1. Unmet Medical Needs and Market Demand

The prevalence of [target disease/condition] continues to rise globally, driven by demographic shifts and increasing disease awareness. According to [relevant epidemiological studies], the global burden of [disease] is projected to reach [specific figures] by [year]. Current therapies are often limited by [limitations, e.g., adverse effects, resistance, or suboptimal efficacy], creating a sizable unmet need.

ARBLI has the potential to fill critical gaps, especially if it demonstrates [advantages such as better safety profile, improved efficacy, ease of administration]. Its success hinges on distinguishing clinical benefits that outperform existing therapeutic options.

2. Competitive Landscape

The pharmaceutical market for [indication] features several mature products and pipeline candidates. Key competitors include [name major drugs or classes], which collectively command significant market shares. However, ARBLI's unique attributes could confer a competitive advantage, especially if it receives regulatory approval for [specific indication or broader label].

Strategic partnerships and licensing agreements are also shaping the competitive paradigm, influencing market access and valuation. For instance, collaboration with established firms can accelerate commercialization and expand geographic reach.

3. Regulatory and Reimbursement Environment

Navigating regulatory pathways remains fundamental. Accelerated approval programs such as [breakthrough therapy, priority review] could expedite market entry, reducing time-to-market and associated costs [2]. Moreover, reimbursement policies significantly impact financial viability; positive health technology assessments and favorable pricing negotiations increase market penetration potential.

In markets with high unmet needs, regulatory agencies may offer expedited review processes, while reimbursement landscape varies between countries, influencing revenue forecasts.

4. Manufacturing and Supply Chain Considerations

Scalability and supply chain resilience are critical. Ensuring consistent quality and meeting global demand necessitate robust manufacturing processes. Pharmaceutical companies investing early in manufacturing capacity can mitigate risks and optimize launch timing, directly influencing financial outcomes.

Financial Trajectory

1. Revenue Projections

If ARBLI secures regulatory approval within [anticipated timeline, e.g., 12-24 months], revenue generation could commence in [year]. Based on epidemiological data and pricing models, conservative estimates project peak annual sales of [$X billion] by [year], contingent on market penetration rates and reimbursement approval.

Market adoption is likely to reflect the drug’s clinical differentiation, payer acceptance, and competitor dynamics. For instance, if ARBLI captures [specific market share]% of the [indication] market, this could translate into revenues of [$Y billion] annually.

2. Cost Structure and Investment

Development costs encompass clinical trial expenses, regulatory submissions, manufacturing setup, and marketing. The estimated R&D expenditure for ARBLI from Phase I to approval stands at approximately [$Z million], with subsequent commercialization costs potentially adding [$A million] annually.

Return on investment (ROI) will depend on the drug's approval timeline, market launch strategy, and sales growth. While high upfront investments pose risks, successful commercialization promises substantial profit margins given the potential for premium pricing in therapeutically underserved segments.

3. Market Penetration and Growth Drivers

Post-approval, growth hinges on factors such as:

• Physician and patient acceptance
• Reimbursement approval
• Global expansion, especially in emerging markets
• Lifecycle management through indications or combination therapies

Advancements in digital health and real-world evidence collection can accelerate adoption and improve financial outlooks.

4. Risks and Mitigation Strategies

Financial forecasts must account for risks, including:

• Clinical failure or safety concerns that delay or deny approval.
• Competitive entries that diminish market share.
• Pricing pressures in highly regulated markets.
• Regulatory hurdles in key geographies.

Proactive engagement with regulators, strategic partnerships, and robust post-market surveillance can help mitigate these risks.

Market Entry and Commercialization Strategies

Successful market penetration requires a tailored approach:

• Partnerships with healthcare providers for education and adoption.
• Engagement with payers to ensure reimbursement pathways.
• Differentiated marketing highlighting ARBLI's clinical advantages.
• Expansion into global markets through licensing agreements and regional collaborations.

Key Drivers of Financial Success

• Differentiated clinical profile and unmet need addressal.
• Expedited regulatory pathways.
• Strategic partnerships and licensing deals.
• Efficient manufacturing and supply chain management.
• Early payer engagement.

Conclusion

ARBLI's market and financial prospects are promising, conditioned on successful clinical validation, regulatory approval, and strategic market execution. While inherent risks remain—typical of novel therapeutics—the drug’s potential to address significant unmet needs makes it a compelling candidate for sustained growth.

Key Takeaways

• ARBLI stands at the cusp of transforming treatment paradigms within its indication, contingent on positive clinical trial outcomes and regulatory support.
• Market dynamics favor innovations that resolve unmet clinical needs, with growth driven by epidemiological trends and therapeutic differentiation.
• Regulatory strategies such as accelerated approval can significantly shorten time-to-market, enhancing financial returns.
• Early engagement with payers ensures reimbursement approval, a critical factor in revenue realization.
• Building a resilient supply chain and leveraging global partnerships will optimize commercialization and revenue growth.

FAQs

Q1. When is ARBLI expected to receive regulatory approval?
The timeline depends on ongoing clinical data. If all phases proceed without major setbacks, regulatory submissions could occur within [estimated timeframe, e.g., 12-18 months], with approval possibly granted within [another 6-12 months] post-submission.

Q2. What are the primary competitors for ARBLI?
Current competitors include [list of main drugs or therapy classes], which may have established market presence but lack certain advantages ARBLI offers, such as [improved safety, efficacy, or administration benefits].

Q3. How does reimbursement impact ARBLI’s market success?
Reimbursement is crucial for commercial viability. Favorable health technology assessments and pricing negotiations enable wider access, directly influencing sales volumes and revenue.

Q4. What are the major risks associated with ARBLI's market launch?
Risks include clinical failure, regulatory delays, high development costs, competitive entries, and pricing pressures. Strategic planning and risk mitigation are essential.

Q5. How can ARBLI leverage global markets for growth?
International expansion through regional licensing, filing strategies aligned with market needs, and adaptable pricing models can amplify growth potential in emerging and developed markets.

---

References

[1] Source detailing ARBLI’s mechanism of action and clinical data.

[2] Regulatory guidelines and accelerated approval pathways by FDA and EMA.